GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Catalyst Pharmaceuticals Inc (NAS:CPRX) » Definitions » E10

Catalyst Pharmaceuticals (Catalyst Pharmaceuticals) E10 : $0.17 (As of Mar. 2024)


View and export this data going back to 2006. Start your Free Trial

What is Catalyst Pharmaceuticals E10?

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller P/E calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years.

Catalyst Pharmaceuticals's adjusted earnings per share data for the three months ended in Mar. 2024 was $0.190. Add all the adjusted EPS for the past 10 years together and divide 10 will get our e10, which is $0.17 for the trailing ten years ended in Mar. 2024.

During the past 12 months, Catalyst Pharmaceuticals's average E10 Growth Rate was 142.90% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the E10 growth rate using E10 data.

During the past 13 years, the highest 3-Year average E10 Growth Rate of Catalyst Pharmaceuticals was 45.00% per year. The lowest was 4.20% per year. And the median was 11.35% per year.

As of today (2024-06-02), Catalyst Pharmaceuticals's current stock price is $16.175. Catalyst Pharmaceuticals's E10 for the quarter that ended in Mar. 2024 was $0.17. Catalyst Pharmaceuticals's Shiller PE Ratio of today is 95.15.

During the past 13 years, the highest Shiller PE Ratio of Catalyst Pharmaceuticals was 950.50. The lowest was 86.59. And the median was 141.05.


Catalyst Pharmaceuticals E10 Historical Data

The historical data trend for Catalyst Pharmaceuticals's E10 can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Catalyst Pharmaceuticals E10 Chart

Catalyst Pharmaceuticals Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
E10
Get a 7-Day Free Trial Premium Member Only Premium Member Only -0.22 -0.12 -0.05 0.04 0.14

Catalyst Pharmaceuticals Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
E10 Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.07 0.11 0.10 0.14 0.17

Competitive Comparison of Catalyst Pharmaceuticals's E10

For the Biotechnology subindustry, Catalyst Pharmaceuticals's Shiller PE Ratio, along with its competitors' market caps and Shiller PE Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Catalyst Pharmaceuticals's Shiller PE Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Catalyst Pharmaceuticals's Shiller PE Ratio distribution charts can be found below:

* The bar in red indicates where Catalyst Pharmaceuticals's Shiller PE Ratio falls into.



Catalyst Pharmaceuticals E10 Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller P/E calculation. When we calculate the today's Shiller P/E ratio of a stock, we use today's price divided by E10.

What is E10? How do we calculate E10?

E10 is the average of the inflation adjusted earnings of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the E10 of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the earnings from 2001 through 2010.

We adjusted the earnings of 2001 earnings data with the total inflation from 2001 through 2010 to the equivalent earnings in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart earned $1 a share in 2001, then the 2001's equivalent earnings in 2010 is $1.4 a share. If Wal-Mart earns $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 earnings in 2010 is $1.35. So on and so forth, you get the equivalent earnings of past 10 years. Then you add them together and divided the sum by 10 to get E10.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, Catalyst Pharmaceuticals's adjusted earnings per share data for the three months ended in Mar. 2024 was:

Adj_EPS= Earnings per Share (Diluted) /CPI of Mar. 2024 (Change)*Current CPI (Mar. 2024)
=0.19/131.7762*131.7762
=0.190

Current CPI (Mar. 2024) = 131.7762.

Catalyst Pharmaceuticals Quarterly Data

per share eps CPI Adj_EPS
201406 -0.050 100.560 -0.066
201409 -0.070 100.428 -0.092
201412 -0.050 99.070 -0.067
201503 -0.070 99.621 -0.093
201506 -0.060 100.684 -0.079
201509 -0.050 100.392 -0.066
201512 -0.070 99.792 -0.092
201603 -0.070 100.470 -0.092
201606 -0.060 101.688 -0.078
201609 -0.050 101.861 -0.065
201612 -0.050 101.863 -0.065
201703 -0.060 102.862 -0.077
201706 -0.050 103.349 -0.064
201709 -0.050 104.136 -0.063
201712 -0.060 104.011 -0.076
201803 -0.060 105.290 -0.075
201806 -0.060 106.317 -0.074
201809 -0.080 106.507 -0.099
201812 -0.140 105.998 -0.174
201903 -0.010 107.251 -0.012
201906 0.100 108.070 0.122
201909 0.130 108.329 0.158
201912 0.070 108.420 0.085
202003 0.100 108.902 0.121
202006 0.090 108.767 0.109
202009 0.410 109.815 0.492
202012 0.110 109.897 0.132
202103 0.070 111.754 0.083
202106 0.110 114.631 0.126
202109 0.100 115.734 0.114
202112 0.090 117.630 0.101
202203 0.120 121.301 0.130
202206 0.200 125.017 0.211
202209 0.200 125.227 0.210
202212 0.220 125.222 0.232
202303 0.260 127.348 0.269
202306 0.330 128.729 0.338
202309 -0.290 129.860 -0.294
202312 0.310 129.419 0.316
202403 0.190 131.776 0.190

Add all the adjusted EPS together and divide 10 will get our e10.


Catalyst Pharmaceuticals  (NAS:CPRX) E10 Explanation

If a company grows much fast than inflation, E10 may underestimate the company's earnings power. Shiller PE Ratio can seem to be too high even the actual P/E is low.

For the Shiller P/E, the earnings of the past 10 years are inflation-adjusted and averaged. The result is used for P/E calculation. Since it looks at the average over the last 10 years, the Shiller P/E is also called PE10.

The Shiller P/E was first used by professor Robert Shiller to measure the valuation of the overall market. The same calculation is applied here to individual companies.

Catalyst Pharmaceuticals's Shiller P/E Ratio of today is calculated as

Shiller PE Ratio=Share Price/E10
=16.175/0.17
=95.15

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

During the past 13 years, the highest Shiller P/E Ratio of Catalyst Pharmaceuticals was 950.50. The lowest was 86.59. And the median was 141.05.


Be Aware

Shiller PE Ratio works better for cyclical companies. It gives you a better idea on the company's real earnings power.


Catalyst Pharmaceuticals E10 Related Terms

Thank you for viewing the detailed overview of Catalyst Pharmaceuticals's E10 provided by GuruFocus.com. Please click on the following links to see related term pages.


Catalyst Pharmaceuticals (Catalyst Pharmaceuticals) Business Description

Traded in Other Exchanges
Address
355 Alhambra Circle, Suite 801, Coral Gables, FL, USA, 33134
Catalyst Pharmaceuticals Inc is a biopharmaceutical company. It focuses on developing and commercializing innovative therapies for people with rare, debilitating, chronic neuromuscular and neurological diseases. It offers Firdapse, a proprietary form of amifampridine phosphate for the treatment of patients with Lambert-Eaton myasthenic syndrome.
Executives
Molly Harper director 355 ALHAMBRA CIRCLE, SUITE 801, CORAL GABLES FL 33134
David S Tierney director C/O ABLE LABORATORIES, INC., 6 HOLLYWOOD COURT, CN 1013, SOUTH PLAINFIELD NJ 07080
Alicia Grande officer: Chief Accounting Officer 220 MIRACLE MILE, SUITE 234, CORAL GABLES FL 33134
Gary Ingenito officer: Chief Medical Officer 355 ALHAMBRA CIRCLE, SUITE 1500, CORAL GABLES FL 33134
Steve Miller officer: VP Development & Management 220 MIRACLE MILE, SUITE 234, CORAL GABLES FL 33134
Tamar Thompson director C/O AVIDITY BIOSCIENCES, INC., 10975 N. TORREY PINES RD., SUITE 150, LA JOLLA CA 92037
Patrick J Mcenany director, 10 percent owner, officer: President and Chief Executive C/O THERMOGENESIS CORP, 2711 CITRUS ROAD, RANCHO CORDOVA CA 95742
Carmen Jeffrey Del officer: Chief Commercial Officer 355 ALHAMBRA CIRCLE, SUITE 801, CORAL GABLES FL 33134
Brian Elsbernd officer: Chief Compliance/Legal Officer 355 ALHAMBRA CIRCLE, CORAL GABLES FL 33134
Philip H Coelho director C/O THERMOGENESIS CORP, 2711 CITRUS ROAD, RANCHO CORDOVA CA 95742
Charles B O'keeffe director 220 MIRACLE MILE, SUITE 234, CORAL GABLES FL 33134
Donald A Denkhaus director 355 ALHAMBRA CIRCLE, SUITE 1500, CORAL GABLES FL 33134
Preethi Sundaram officer: Chief Product Devel. Officer 355 ALHAMBRA CIRCLE, SUITE 801, CORAL GABLES FL 33134
Daniel Brennan officer: Chief Commercial Officer C/O INSYS THERAPEUTICS, INC, 1333 SOUTH SPECTRUM BLVD, SUITE 100, CHANDLER AZ 85286
M Douglas Winship officer: V.P. of Regulatory Operations 220 MIRACLE MILE, SUITE 234, CORAL GABLES FL 33134

Catalyst Pharmaceuticals (Catalyst Pharmaceuticals) Headlines

From GuruFocus

Should Investors Worry About Catalyst Pharmaceuticals Inc's Insider Sells?

By GuruFocus Research GuruFocus Editor 05-18-2023

Insider Alert: An Insider Just Sold Catalyst Pharmaceuticals Inc Shares

By GuruFocus Research GuruFocus Editor 05-19-2023